Showing 1 - 2 results of 2 for search 'Keith D. Wilner', query time: 0.02s Refine Results
  1. 1
    Effect of the patient information brochure in communicating the risks associated with crizotinib treatment to patients with non‐small cell lung cancer (NSCLC) in Europe

    Effect of the patient information brochure in communicating the risks associated with crizotinib treatment to patients with non‐small cell lung cancer (NSCLC) in Europe by Kui Huang, Terri Madison, Beatrice Wehler, Marcello Tiseo, Keith D. Wilner, Jingping Mo

    Published 2020-04-01
    Get full text
    Article
  2. 2
    Final Overall Survival, Safety, and Quality of Life Results From a Phase 2 Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced NSCLC

    Final Overall Survival, Safety, and Quality of Life Results From a Phase 2 Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced NSCLC by Yi-Long Wu, MD, Shun Lu, MD, PhD, James Chih-Hsin Yang, MD, PhD, Jianying Zhou, MD, Takashi Seto, MD, Myung-Ju Ahn, MD, PhD, Wu-Chou Su, MD, Noboru Yamamoto, MD, PhD, Dong-Wan Kim, MD, PhD, Jolanda Paolini, MSc, Tiziana Usari, BSc, Laura Iadeluca, PhD, Keith D. Wilner, PhD, Koichi Goto, MD, PhD

    Published 2022-10-01
    Get full text
    Article

Search Tools: